文献速递脑血管病

氯吡格雷多基因风险评分预测轻型卒中或TIA疗效——CHANCE试验事后分析

Polygenic Risk Score for the Efficacy of Clopidogrel in Patients With Minor Stroke or Transient Ischemic Attack: A Post Hoc Analysis of the CHANCE Trial.
PubMed 文献 · Stroke · 2025-03-07

该研究为CHANCE试验事后分析,纳入2905例患者,基于7个基因16个单核苷酸多态性构建多基因风险评分。发现高PRS与90天新发卒中风险升高相关(Ptrend=0.01),低PRS患者双抗较单抗预防1年复合血管事件更有效(调整HR 0.47),高PRS组为0.84(交互P=0.03)。PRS预测90天新发卒中的C统计量为0.57,高于ABCD-GENE评分的0.52。

要点

  • 高多基因风险评分与90天新发卒中风险升高相关(Ptrend=0.01)。
  • 低PRS者双抗较单抗预防1年复合血管事件更有效(调整HR 0.47 vs 高PRS组0.84,交互P=0.03)。
  • PRS预测90天新发卒中C统计量0.57,ABCD-GENE评分为0.52。

核心结论

  • 整合多基因的多基因风险评分可能提高轻型卒中或短暂性脑缺血发作患者短期和长期二级预防策略的精准性。

研究设计与样本

  • CHANCE试验(2009年10月至2012年7月在中国纳入5170例患者)的事后分析,纳入2905例患者。
  • 选取参与氯吡格雷代谢的7个基因上的16个单核苷酸多态性,通过相加各单核苷酸多态性计算多基因风险评分。
  • 采用Cox比例风险回归模型估计风险比(HR)及95%CI,用C统计量评估预测价值并与既往验证模型比较。
  • 主要结局为90天内新发卒中。

主要发现

  • 多基因风险评分升高与90天内新发卒中风险增加相关(Ptrend=0.01)。
  • 双联抗血小板治疗与阿司匹林单药预防1年复合血管事件的疗效在低PRS患者(调整HR 0.47 [95%CI 0.31-0.71])与高PRS患者(调整HR 0.84 [95%CI 0.60-1.18])间存在显著差异(交互P=0.03)。
  • 在接受双联抗血小板治疗的患者中,较高的多基因风险评分与90天新发卒中和复合血管事件风险增加相关(每增加1个标准差调整HR 1.51 [95%CI 1.15-1.99]),1年时亦相关(每增加1个标准差调整HR 1.34 [95%CI 1.08-1.67])。
  • 本研究构建的PRS预测90天新发卒中的C统计量为0.57(95%CI 0.52-0.62),ABCD-GENE评分为0.52(95%CI 0.48-0.55)。

关键数值与推荐

  • 多基因风险评分由7个基因上16个单核苷酸多态性相加计算。
  • 低PRS患者双抗vs阿司匹林单药预防1年复合血管事件:调整HR 0.47(95%CI 0.31-0.71)。
  • 高PRS患者双抗vs阿司匹林单药预防1年复合血管事件:调整HR 0.84(95%CI 0.60-1.18),交互P=0.03。
  • 双抗治疗患者中PRS每增加1个标准差,90天新发卒中及复合血管事件调整HR 1.51(95%CI 1.15-1.99),1年调整HR 1.34(95%CI 1.08-1.67)。
  • PRS预测90天新发卒中C统计量0.57(95%CI 0.52-0.62),ABCD-GENE评分0.52(95%CI 0.48-0.55)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is recommended for secondary prevention in patients with a minor stroke or transient ischemic attack. However, the effectiveness of DAPT can be significantly influenced by genetic variations. This study aimed to estimate the impact of multiple single-nucleotide polymorphisms across various genes on DAPT efficacy using polygenic risk score (PRS). METHODS: In this post hoc analysis, we included 2905 patients from the CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events), which enrolled a total of 5170 patients in China between October 2009 and July 2012. The primary outcome was new stroke within 90 days. Sixteen single-nucleotide polymorphisms across 7 genes involved in clopidogrel metabolism were selected for PRS development. PRS were calculated by summing single-nucleotide polymorphisms from each individual. The Cox proportional-hazards regression model was utilized to estimate the hazard ratio (HR) and 95% CIs of PRS. The predictive value of PRS was estimated by C statistic and compared with a previously validated model. RESULTS: The elevated PRSs were associated with an increased risk of new stroke within 90 days (Ptrend=0.01). The efficacy of DAPT versus aspirin alone in preventing 1-year composite vascular events was significantly different between patients with low (adjusted HR, 0.47 [95% CI, 0.31-0.71]) and high PRSs (adjusted HR, 0.84 [95% CI, 0.60-1.18]; Pinteraction=0.03). In patients receiving DAPT, higher PRSs were associated with increased risk of new stroke and composite vascular events at 90 days (adjusted HR per SD increase was 1.51 [95% CI, 1.15-1.99]) and at 1 year (adjusted HR per SD increase was 1.34 [95% CI, 1.08-1.67]). The C statistic for predicting 90-day new stroke using the PRS developed in this study was 0.57 (95% CI, 0.52-0.62), compared with 0.52 (95% CI, 0.48-0.55) for the ABCD-GENE score. CONCLUSIONS: Using PRS integrating multiple genes may enhance the precision of secondary prevention strategies for patients with minor stroke or transient ischemic attack in the short and long term. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00979589.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Qiu X, Jiang Y, Gu HQ, et al. Polygenic Risk Score for the Efficacy of Clopidogrel in Patients With Minor Stroke or Transient Ischemic Attack: A Post Hoc Analysis of the CHANCE Trial. Stroke. 2025. PMID: 40052280. doi:10.1161/STROKEAHA.124.049140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。